Aimmune Therapeutics

What Aimmune Therapeutics does

Aimmune Therapeutics is a clinical- and commercial-stage biopharmaceutical company founded in 2011 and headquartered in Brisbane, California, that develops oral immunotherapy (OIT) treatments for food allergies. Its lead asset, Palforzia (formerly AR101), is a peanut-derived oral biologic regimen that received FDA approval in January 2020 as the first treatment indicated for peanut allergy in children and adolescents ages 4 through 17, and is administered under a Risk Evaluation and Mitigation Strategy (REMS) with structured up-dosing in supervised clinical settings. The company monetizes through prescription drug sales to patients via specialty pharmacies, allergists, and pediatricians, with go-to-market expanded through integration into Nestlé Health Science's Pharmaceutical Therapies commercial and medical-affairs infrastructure across North America, 16 European countries, and Australia. In February 2020, Nestlé Health Science completed a $2.1 billion acquisition of Aimmune, taking the company private; Aimmune now operates as a wholly-owned subsidiary of Nestlé Health Science USA, with 501–1,000 employees supporting continued food-allergy pipeline and Palforzia commercialization. The business model is therefore a specialty biopharma commercial-stage franchise embedded within a global nutrition and pharmaceutical parent's distribution, reimbursement, and regulatory footprint, with revenue not separately disclosed at the subsidiary level.

Name

Aimmune Therapeutics

Legal name

Aimmune Therapeutics, Inc.

Website

https://aimmune.com

Company type

Private

Founded year

2011

Operating status

Acquired

Headcount range

501–1,000 employees

Short description

Aimmune Therapeutics is a biopharmaceutical company developing oral immunotherapies for food allergies. Its lead product, Palforzia, was the first FDA-approved peanut allergy treatment. Founded in 2011 and now a wholly-owned subsidiary of Nestlé Health Science USA following a 2020 acquisition.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Allergy Immunotherapy Biologics (allergen extracts, desensitization) (HLAAAEAI)

akta.pro secondary industries

Allergen Immunotherapy (SCIT/SLIT) Services (HLAKAAAF), Respiratory & Allergy Pharmaceuticals (HLAIAAAH), Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral) (HLAAAEAF)

Keywords

• Oral immunotherapy
• Peanut allergy treatment
• Allergenic extracts
• Biopharmaceutical products
• Food allergy therapeutics

Headquarters

HQ city

Brisbane

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Core offering

Aimmune Therapeutics is a biopharmaceutical company that develops and commercializes oral immunotherapies for food allergies. Its lead product, Palforzia (formerly AR101), is an FDA-approved oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut in patients aged 4 through 17 years with a confirmed diagnosis of peanut allergy.

Differentiator

Problem solved

Functional benefit

Brands

• Palforzia: The first FDA-approved oral immunotherapy for peanut allergy, formerly known as AR101. Marketed for children and adolescents ages 4 through 17 with a confirmed diagnosis of peanut allergy.

Products and services

• Palforzia (formerly AR101) Palforzia is an oral immunotherapy product designed to mitigate allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut. It is indicated for children and adolescents ages 4 through 17 with a confirmed diagnosis of peanut allergy, and is used under the supervision of an allergist as part of a Risk Evaluation and Mitigation Strategy (REMS) program.

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves6 records

Expansion highlights4 records

Emerging players

• Aravax: Aravax is a clinical-stage company developing peptide-based immunotherapies for peanut allergy, representing an emerging food allergy immunotherapy competitor comparable to Aimmune's core focus.
• Prota Therapeutics: Prota Therapeutics is developing an oral immunotherapy for peanut allergy (PRT120), directly comparable to Palforzia as a clinical-stage peanut OIT competitor.
• Alladapt Immunotherapeutics: Alladapt is a clinical-stage biotech developing multi-food allergen oral immunotherapy, directly comparable to Aimmune's OIT modality for food allergy desensitization.

Broad incumbents

• Novartis: Novartis is a broad biopharma with respiratory and immunology franchises overlapping Aimmune's allergy therapeutic focus, and has the scale and commercial reach comparable to Nestlé Health Science as a parent competitor.
• ALK-Abelló: ALK-Abelló is the global leader in allergy immunotherapy (SCIT/SLIT) for respiratory and venom allergies, comparable to Aimmune as a commercial-stage allergy immunotherapy company expanding into food allergy.
• Sanofi: Sanofi markets Dupixent (dupilumab), which is approved for various allergic conditions and has been studied in food allergy adjunction settings, positioning it as a broad incumbent competing in the same therapeutic category.
• Regeneron: Regeneron co-developed Dupixent and has active immunology and food allergy research programs, making it a relevant broad incumbent biopharma peer to Aimmune's biologic allergy work.
• Genentech (Roche): Genentech has active immunology research including IgE-mediated disease programs, making it a relevant broad incumbent biopharma operating in the same therapeutic biology as Aimmune.

Direct peers

• DBV Technologies: DBV Technologies is developing Viaskin Peanut, an epicutaneous immunotherapy for peanut allergy, making it the most directly comparable competitor to Aimmune's Palforzia in the same indication and patient population.
• Stallergenes Greer: Stallergenes Greer is a specialty biopharmaceutical company focused on allergy immunotherapy (subcutaneous and sublingual), making it a directly comparable allergy desensitization therapeutics peer to Aimmune.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights5 records

Customer concentration

• Xx.com/aimmune

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds5 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aimmune Therapeutics